We are live on ! Find out more
FMS icon

Fresenius Medical Care

23.13 USD
+0.51
2.25%
At close Updated Oct 29, 4:00 PM EDT
Pre-market
After hours
22.83
-0.30
1.3%
1 day
2.25%
5 days
3.17%
1 month
3.86%
3 months
-6.96%
6 months
4.38%
Year to date
-1.62%
1 year
-14.01%
5 years
-30.39%
10 years
-43%
 

About: Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

Employees: 108,165

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 46.7%
Negative 20%
Positive
Zacks Investment Research
6 days ago
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Neutral
PRNewsWire
8 days ago
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Neutral
PRNewsWire
10 days ago
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
Neutral
Zacks Investment Research
22 days ago
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Positive
Zacks Investment Research
1 month ago
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Neutral
PRNewsWire
1 month ago
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Neutral
Zacks Investment Research
1 month ago
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Positive
Zacks Investment Research
1 month ago
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Positive
Morningstar
2 months ago
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
3 Cheap International Stocks to Buy
Neutral
Zacks Investment Research
2 months ago
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Price charts implemented using Lightweight Charts™